Xu W, Filppula S A, Mercier R, Yaddanapudi S, Pavlopoulos S, Cai J, Pierce W M, Makriyannis A
Department of Pharmaceutical Sciences, University of Connecticut, 372 Fairfield Road, U-2092, Storrs, CT 06269, USA.
J Pept Res. 2005 Sep;66(3):138-50. doi: 10.1111/j.1399-3011.2005.00283.x.
The cannabinoid receptor 1 (CB1) cannabinoid receptor is an essential component of the cannabinergic system. It has been recognized as a therapeutic target for treating numerous diseases and is currently receiving considerable attention by the pharmaceutical community. Target-based drug design, utilizing three-dimensional information of receptor structure and ligand-binding motifs, requires significant amounts of purified protein. To facilitate the purification of CB1, we have expressed the receptor fused to various epitope tags using the baculovirus expression system. In addition, expression levels and ligand-binding profiles corresponding to the expressed fusion proteins have been compared. C-terminal histidine (His)-tagged CB1 gave a Bmax higher than most other systems previously reported in the literature, and was selected for subsequent metal affinity chromatography purification and mass spectroscopic (MS) analysis. Moreover, cells expressing C-terminal His-tagged CB1 were shown to inhibit forskolin-stimulated cyclic adenosine 3',5'-monophosphate (cAMP) production in a concentration-dependent manner in the presence of CP-55,940, confirming the expressed receptor's functional characteristics. A Western blot analysis of the purified receptor showed several forms of CB1, the most abundant being a 57 kDa monomeric protein. The purified CB1 preparations were subjected to protein digestion followed by MS. Fragments corresponding to >70% of the receptor were identified by this method, confirming the identity and purity of the expressed protein. The work presented here demonstrates that epitope-tagged CB1 can be expressed in sufficient amounts and purified to homogeneity for MS analysis. Moreover, these results will serve as a basis for future experiments aimed at characterizing the ligand-binding domains using covalently reacting receptor probes.
大麻素受体1(CB1)是大麻素系统的重要组成部分。它已被公认为治疗多种疾病的治疗靶点,目前正受到制药界的广泛关注。基于靶点的药物设计利用受体结构和配体结合基序的三维信息,需要大量纯化蛋白。为便于CB1的纯化,我们使用杆状病毒表达系统表达了与各种表位标签融合的受体。此外,还比较了与表达的融合蛋白相对应的表达水平和配体结合谱。C末端组氨酸(His)标签的CB1的最大结合容量(Bmax)高于文献中先前报道的大多数其他系统,并被选用于后续的金属亲和层析纯化和质谱(MS)分析。此外,在存在CP-55,940的情况下,表达C末端His标签CB1的细胞显示出以浓度依赖的方式抑制福斯高林刺激的环磷酸腺苷(cAMP)产生,证实了表达受体的功能特性。对纯化受体的蛋白质印迹分析显示了几种形式的CB1,最丰富的是一种57 kDa的单体蛋白。对纯化的CB1制剂进行蛋白消化,然后进行质谱分析。通过该方法鉴定出对应于>70%受体的片段,证实了表达蛋白的身份和纯度。本文的工作表明,表位标签的CB1可以大量表达并纯化至同质以进行质谱分析。此外,这些结果将作为未来旨在使用共价反应受体探针表征配体结合域的实验的基础。